ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Biomea Fusion Inc

Biomea Fusion Inc (BMEA)

14.95
-0.41
(-2.67%)
Closed March 29 04:00PM
14.95
0.00
(0.00%)
After Hours: 07:45PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
14.95
Bid
14.72
Ask
15.45
Volume
809,848
14.85 Day's Range 15.71
8.125 52 Week Range 43.69
Market Cap
Previous Close
15.36
Open
15.37
Last Trade
4
@
15.4499
Last Trade Time
Financial Volume
$ 12,326,636
VWAP
15.2209
Average Volume (3m)
979,690
Shares Outstanding
35,705,786
Dividend Yield
-
PE Ratio
-6.52
Earnings Per Share (EPS)
-2.29
Revenue
-
Net Profit
-81.83M

About Biomea Fusion Inc

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BMEA. The last closing price for Biomea Fusion was $15.36. Over the last year, Biomea Fusion shares have traded in a share price range of $ 8.125 to $ 43.69.

Biomea Fusion currently has 35,705,786 shares outstanding. The market capitalization of Biomea Fusion is $533.80 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -6.52.

BMEA Latest News

Form 8-K - Current report

false 0001840439 0001840439 2024-03-06 2024-03-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT...

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2...

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 8-K - Current report

4th Floor false 0001840439 0001840439 2024-01-09 2024-01-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT...

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.05-6.56251617.2514.773795515.8144053CS
4-4.05-21.31578947371919.354914.24132310916.52305561CS
120.151.0135135135114.820.2113.440797969016.66578051CS
261.238.9650145772613.7222.748.125106735415.12082149CS
52-8.05-352343.698.125100220320.98010042CS
156-5.05-25.252043.692.8443025418.80176141CS
260-5.05-25.252043.692.8443025418.80176141CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

Your Recent History

Delayed Upgrade Clock